Monthly Oncology Tumor Boards: Systemic Therapy Selection in Metastatic Castration-Resistant Prostate Cancer
The selection of systemic treatments in various lines of therapy for patients with metastatic castration-resistant prostate cancer (CRPC) has become more and more complicated over the last several years. Clinicians who work with patients with metastatic CRPC need to be educated on these updates so that they can help their patients make optimal treatment choices across lines of therapy.
Category
  • Prostate Cancer
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date July 21, 2021